MA26608A1 - Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque. - Google Patents

Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.

Info

Publication number
MA26608A1
MA26608A1 MA25465A MA25465A MA26608A1 MA 26608 A1 MA26608 A1 MA 26608A1 MA 25465 A MA25465 A MA 25465A MA 25465 A MA25465 A MA 25465A MA 26608 A1 MA26608 A1 MA 26608A1
Authority
MA
Morocco
Prior art keywords
preparation
treatment
pharmaceutical composition
heart failure
heart
Prior art date
Application number
MA25465A
Other languages
English (en)
Inventor
Liang Chen Yuhpyng
Andrea Fossa Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26608A1 publication Critical patent/MA26608A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25465A 1998-02-17 1999-02-16 Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque. MA26608A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7493498P 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
MA26608A1 true MA26608A1 (fr) 2004-12-20

Family

ID=22122537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25465A MA26608A1 (fr) 1998-02-17 1999-02-16 Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.

Country Status (28)

Country Link
US (1) US6043260A (fr)
EP (1) EP0951906A1 (fr)
JP (1) JPH11292766A (fr)
KR (1) KR19990072616A (fr)
CN (1) CN1231176A (fr)
AP (1) AP9901464A0 (fr)
AR (1) AR017723A1 (fr)
AU (1) AU1732999A (fr)
BG (1) BG103180A (fr)
BR (1) BR9900653A (fr)
CA (1) CA2262252C (fr)
EA (1) EA199900124A3 (fr)
GT (1) GT199900015A (fr)
HR (1) HRP990054A2 (fr)
HU (1) HUP9900386A3 (fr)
ID (1) ID23218A (fr)
IL (1) IL128531A0 (fr)
IS (1) IS4975A (fr)
MA (1) MA26608A1 (fr)
NO (1) NO990722L (fr)
OA (1) OA10976A (fr)
PA (1) PA8467401A1 (fr)
PE (1) PE20000266A1 (fr)
PL (1) PL331507A1 (fr)
SG (1) SG81261A1 (fr)
TN (1) TNSN99024A1 (fr)
TR (1) TR199900328A2 (fr)
ZA (1) ZA991220B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
HUP0204272A3 (en) * 2000-01-18 2005-03-29 Pfizer Prod Inc Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA04007026A (es) 2002-02-22 2004-10-11 Pharmacia & Up John Company Pirimidinonas y pirimidintionas sustituidas.
EP1485384A1 (fr) * 2002-03-13 2004-12-15 Pharmacia & Upjohn Company LLC Derives de pyrazolo(1,5-a)pyridine utilises en tant que modulateurs du neurotransmetteur
JP2005533014A (ja) * 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
US20040116444A1 (en) * 2002-09-12 2004-06-17 Corbett Jeffrey W. Substituted 1,4-pyrazine derivatives
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
EP1565454A1 (fr) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Composes de pyrazine en tant que modulateurs de crf
BRPI0409649A (pt) * 2003-04-23 2006-04-25 Pharmacia & Upjohn Co Llc pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
CA2523072A1 (fr) * 2003-05-07 2004-11-18 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridaziniques
JP2006525993A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｒｆ１受容体拮抗剤である化合物
MXPA05012081A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Derivados de pirimidina sustituidos.
CA2525195A1 (fr) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Pyrazinones a titre d'antagonistes du recepteur de crf1 dans le traitement des troubles du systeme nerveux central
WO2005089639A2 (fr) * 2004-03-16 2005-09-29 Talarico M D Matthew T Procede de deregulation vasculaire
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique

Also Published As

Publication number Publication date
NO990722D0 (no) 1999-02-16
HRP990054A2 (en) 2000-02-29
PE20000266A1 (es) 2000-04-07
CA2262252A1 (fr) 1999-08-17
HU9900386D0 (en) 1999-04-28
EA199900124A2 (ru) 1999-08-26
HUP9900386A2 (hu) 1999-11-29
BR9900653A (pt) 2000-10-17
PL331507A1 (en) 1999-08-30
PA8467401A1 (es) 2000-09-29
IL128531A0 (en) 2000-01-31
NO990722L (no) 1999-08-18
BG103180A (bg) 1999-09-30
US6043260A (en) 2000-03-28
OA10976A (en) 2001-11-05
GT199900015A (es) 2000-07-26
EA199900124A3 (ru) 1999-12-29
CA2262252C (fr) 2006-01-10
ZA991220B (en) 2000-08-16
IS4975A (is) 1999-08-18
ID23218A (id) 2000-03-30
AR017723A1 (es) 2001-09-12
KR19990072616A (ko) 1999-09-27
TNSN99024A1 (fr) 2005-11-10
HUP9900386A3 (en) 1999-12-28
TR199900328A2 (xx) 1999-10-21
SG81261A1 (en) 2001-06-19
JPH11292766A (ja) 1999-10-26
AP9901464A0 (en) 1999-03-31
EP0951906A1 (fr) 1999-10-27
CN1231176A (zh) 1999-10-13
AU1732999A (en) 1999-09-02

Similar Documents

Publication Publication Date Title
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
MA21682A1 (fr) Procede de preparation d'agents therapeutiques derives de la quainclidine.
MA22481A1 (fr) Procede de preparation d'acides imidazolyl - alcenoiques .
MA23091A1 (fr) Procede de preparation d'agents antiparasitaires .
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
MA23143A1 (fr) Procede pour la preparation de compositions vaccinantes .
MA25223A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
MA21922A1 (fr) Procede de purification d'acides aminomethylene-phosphoniques .
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
MA22443A1 (fr) Procede de preparation d'une composition pharmaceutique .
FR2697248B1 (fr) Procede de preparation du dichlorure d'acide l-5-(2-acetoxy-propionylamino)-2,4,6-triiodo-isophtalique.
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
DZ2619A1 (fr) Procédé pour la préparation d'acides 4-phényl-4-cyanocyclohexanoïques substitués.
FR2715656B1 (fr) Procédé de préparation d'anhydride citraconique.
ATE218856T1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
FR2733227B1 (fr) Procede pour la preparation de 1,1-difluoroethane
DZ2423A1 (fr) Procédé pour la préparation d'acides 4-phényl-4-cyanocyclohexanoiques substitués.
FR2739373B1 (fr) Procede de preparation de catalyseurs d'ammoxydation
EP0990441A4 (fr) Medicament pour le traitement de la nephropathie diabetique
DZ2757A1 (fr) Procédé pour la préparation d'acides hydroxamiques.
FR2668707B1 (fr) Procede de preparation d'une composition pharmaceutique.